Medical Tidbits, Leading Medical News Today

Your place for beaking medical news and career advice from top medical recruiters

FDA Approves Amgen’s New Cholesterol-Lowering Medication Repatha™ (evolocumab)

THOUSAND OAKS, Calif., Aug. 27, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new cholesterol-lowering medication, Repatha™ (evolocumab) Injection. Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, from the blood.1  Repatha is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C; and as an adjunct to diet and other LDL-lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH), who require additional lowering of LDL-C. The effect of Repatha on cardiovascular morbidity and mortality has not been determined. read more

Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total of approximately $7.2 billion, net of cash acquired. As a result of the completion of the merger, the common stock of Receptos is no longer listed for trading on the NASDAQ Global Market or any other exchange and trading ceased at the close of the markets on Thursday, August 27, 2015. read more

Novartis continues commitment to go the last mile in effort to eliminate leprosy

Basel, August 28, 2015 – Novartis has renewed its pledge with the World Health Organization (WHO) to work to end leprosy by extending its donation of multidrug therapy (MDT) medicines to treat leprosy through the year 2020. This five-year agreement includes treatments worth more than USD 40 million and up to USD 2.5 million to support the WHO in handling the donation and logistics. Overall it is expected that the program will reach an estimated 1.3 million patients during the next five years. This is part of the company’s commitment in 2012 to the London Declaration on Neglected Tropical Diseases. read more

Over 550 Women’s Lives Transformed to-Date With Action on Fistula

Astellas today announces that, just over a year on from the launch of Action on Fistula, 582 Kenyan women with obstetric fistula have successfully been treated with life changing reconstructive surgery. One woman treated had waited 51 years for surgery, and the age range of individuals helped so far spans from seven to 90 years old. read more

Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo

Mylan Intends to Launch Formal Offer to Perrigo Shareholders in the Coming Weeks

HERTFORDSHIRE, England and PITTSBURGH, Aug. 28, 2015 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) today announced that its shareholders have approved Mylan’s proposed acquisition of Perrigo Company plc (NYSE: PRGO; TASE) and the related issuance of Mylan ordinary shares to Perrigo’s shareholders at an extraordinary general meeting of shareholders held today. The transaction received the approval of two-thirds of the votes cast at the extraordinary general meeting. In addition, the transaction received support from more than a majority of all outstanding ordinary shares. read more

Subscribe today for leading medical news and career tips.




Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.